Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 6, 2011, Pages 905-925

  Johansson, Anders ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

depression; MCH 1 receptor; melanin concentrating hormone; obesity

Indexed keywords

AMIDE; BENZIMIDAZOLE DERIVATIVE; FUSED CARBON NITROGEN HETEROCYCLE; IMIDAZOLIDINE DERIVATIVE; INDAZOLE DERIVATIVE; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDONE DERIVATIVE; QUINAZOLINE DERIVATIVE;

DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW;

APPETITE DEPRESSANTS; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; OBESITY; PATENTS AS TOPIC; RECEPTORS, SOMATOSTATIN;

EID: 79956212333     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.575063     Document Type: Review

References (131)

1. Schlumberger SE, Talke-Messerer C, Zumsteg U, Eberle AN. Expression of receptors for melanin-concentrating hormone (MCH) in different tissues and cell lines. J Recept Signal Transduct 2002;22(1-4):509-31 (Pubitemid 36169169)
2. Ildiko A-Z, Khawaja X. The role of melanin-concentrating hormone in energy homeostasis and mood disorders. J Mol Neurosci 2009;39(1-2):86-98
3. Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharm 2009;68(6):852-60
4. Nahon J-L. The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. C R Biol 2006;329:623-38 (Pubitemid 44081128)
5. Bednarek MA. Peptide ligands for the Melanin-Concentrating Hormone (MCH) receptor 1. Curr Top Med Chem 2007;7(15):1425-32
6. Jeon M-K, Cheon HG. Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists. Curr Top Med Chem 2009;9:504-38
7. Rivera G, Bocanegra-Garcia V, Galiano S, et al. Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr Top Med Chem 2008;8:504-38
8. Kym PR, Judd AS, Lynch JK, et al. Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. Curr Top Med Chem 2007;7:1471-88 (Pubitemid 47628330)
9. Mendez-Andino JL, Wos JA. MCH -R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007;12(21&22): 972-9 (Pubitemid 350052673)
10. McBriar MD. Recent advances in the discovery of melanin-concentrating hormone receptor antagonists. Curr Opin Drug Discov Dev 2006;9:496
11. Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature 1996;380:243-7 (Pubitemid 26090645)
12. Shimada M, Tritos NA, Lowell BB, et al. Mice lacking melanin- concentrating hormone are hypophagic and lean. Nature 1998;396:670-4
13. Chambers J, Ames RS, Bergsma D, et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein coupled receptor SLC-1. Nature 1999;400:261-5 (Pubitemid 29334140)
14. Saito Y, Nothacker H-P, Wang Z, et al. Molecular characterization of the melanin-concentrating hormone receptor. Nature 1999;400:265-9 (Pubitemid 29334141)
15. Marsh DJ, Weingarth DT, Novi DE, et al. Melanin-concentrating hormone 1 receptor-deficient mice are are lean, hyperactive and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002;99:3240-5 (Pubitemid 34240616)
16. Borowsky B, Durkin M, Ogozalek K, et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002;8(8):825-30
17. Surman DS, Freeman EE, Grabowski JF, et al. 5-(Pyridinon-1-yl)indazoles and 5- (furopyridinon-5-yl)indazoles as MCH-1 antagonists. Bioorg Med Chem Lett 2010;20:7015-19
18. Hadden M, Deering DM, Henderson AJ, et al. Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridine-2 (1H)ones as MCH-1 antagonists for the treatment of obesity. Bioorg Med Chem Lett 2010;20:7020-3
19. Henderson AJ, Deering D, Grabowski JF, et al. Tetrahydrocarboline analogs as MCH-1 antagonists. Bioorg Med Chem Lett 2010;20:2024-7028
20. Suzuki T, Kameda M, Ando M, et al. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:5339-45
21. Ito M, Sakamoto M, Suzuki T, et al. Identification and characterization of a selective radioligand for melanin concentrating hormone 1-receptor (MCH1R). Bioorg Med Chem Lett 2009;19:2835-9
22. Ito M, Ishihara A, Gomori A, et al. Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice. Eur J Pharm 2009;624:77-83
23. Kowalski TJ, Spar BD, Weig BD, et al. Effects of a selective melanin-concentrating hormone 1-receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. Eur J Pharmacol 2006;535:182-91
24. Huang CQ, Baker T, Schwarz D, et al. 1-(4-Amino-phenyl)-pyrrolidin- 3-yl-amine and 6-(3-aminopyrrolidin-1- yl)-pyridin-3-yl-amine derivatives as melaninconcentrating hormone receptor-1 antagonists. Bioorg Med Chem Lett 2005;15:3701-6 (Pubitemid 41038963)
25. Ito M, Ishihara A, Gomori A, et al. Mechanism of the anti-obesity effects induced by a novel Melanin-concentrating hormone 1-receptor antagonist in mice. Br J Pharm 2010;159:374-83
26. Mori M, Harada M, Terao Y, et al. Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor. Biochem Biophys Res Commun 2001;283(5):1013-18 (Pubitemid 32912868)
27. Wang S, Jiang B, O?Neill K, et al.. Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, MCH-R2. J Biol Chem 2001;276(37):34664-70
28. Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists. Life Sci 2007;81(6):423-40 (Pubitemid 47175968)
29. Shimazaki T, Yoshimizu T, Shigeyuki C. Melanin-concentrating hormone MCH1 receptor antagonists. A potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 2006;20(10):801-11 (Pubitemid 44484244)
30. Chaki S, Funakoshi T, Hirota-Okuno S, et al. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 2005;313(2):831-9 (Pubitemid 40604185)
31. Dyck B. Small molecule melanin-concentrating hormone receptor 1(MCH1R) antagonists as anxiolytic and antidepressive agents. Drug Dev Res 2005;65(4):291-300 (Pubitemid 43017110)
32. Ito M, Gomori A, Suzuki J, et al. Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice. J Endocr 2008;198:309-15
33. Parks GS, Okumura SM, Gohil K, Civelli O. Mice lacking melanin concentrating hormone receptor are resistant to seizures. Neurosci Lett 2010;484:104-7
34. Available from: http://www.iddb.com/ Thompson Current Drugs: drug report for AMG-076 2010
35. Andersen D, Storz T, Liu P, et al. Stereoselective synthesis of a MCHr1 antagonist. J Org Chem 2007;72:9648
36. Available from: http://www.iddb.com/ Thompson Current Drugs: drug report for NGD-4715 2010
37. Hertzog DL, Al-Barazanji KA, Barvian KK, et al. MCH R1 antagonists: problems and solutions. Abstracts of Papers, 240th ACS National Meeting MEDI-283; 22 - 26 August 2010; Boston, MA, United States.
38. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharm Ther 2010;87(6):652-62
39. Available from: http://www.iddb.com/ Thompson Current Drugs: drug report for Alb127158(a) 2010
40. Carpenter AJ, Herzog DL. Melanin-concentrating hormone receptor antagonists as potential antiobesity agents. Expert Opin Ther Patents 2002;12(11):1639-46 (Pubitemid 35355901)
41. Browning A. Recent developments in the discovery of melanin-concentrating hormone antagonists: novel antiobesity agents. Expert Opin Ther Patents 2004;14(3):313-25 (Pubitemid 38380269)
42. Dyke HJ, Ray NC. Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity - an update. Expert Opin Ther Patents 2005;15(10):1303-13 (Pubitemid 41600589)
43. Rokosz LL. Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Expert Opin Drug Discov 2007;2(10):1301-27 (Pubitemid 47591275)
44. 7TM Pharma. WO06010446; 2006.
45. Sasmal PK, Sasmal S, Tirumala Rao P, et al. Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists. Bioorg Med Chem Lett 2010;20:5443-8
46. AMRI. WO08086404; 2008.
47. AMRI. WO08086409; 2008.
48. AMRI. WO09015037; 2009.
49. AMRI. WO09089482; 2009.
50. AstraZeneca. WO06068594; 2006.
51. AstraZeneca. WO06130075; 2006.
52. AstraZeneca. WO07078251; 2007.
53. AstraZeneca. WO07011284; 2007.
54. AstraZeneca. WO07011285; 2007.
55. AstraZeneca. WO07011286; 2007.
56. AstraZeneca. WO08020799; 2008.
57. Banyu. WO06038680; 2006 [US20070299070].
58. Banyu. WO05085200; 2005 [US20070208046].
59. Banyu. WO07018248; 2007 [US20100216758].
60. Ando M, Sekino E, Haga Y, et al. Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:5186-90
61. Banyu. WO07024004; 2007 [US20090137587].
62. Banyu. WO07029847; 2007 [US20090264426].
63. Banyu. WO07142217; 2007.
64. Suzuki T, Moriya M, Sakamoto T, et al. Discovery of novel spiro-piperidinederivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:3072-7
65. Banyu. WO04069798; 2004 [US20060106046].
66. Suzuki T, Kameda M, Ando M, et al. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:5339-45
67. Banyu. WO08038692; 2008 [US20090247560].
68. Banyu. WO08047544; 2008.
69. Banyu. WO09041567; 2009/US20100216758; 2010.
70. Banyu. WO09119726; 2009.
71. Banyu. WO20010013595 2010.
72. Biovitrum. WO06114402; 2006.
73. Boehringer Ingelheim. WO07048802; 2007
74. Boehringer Ingelheim. WO08071646; 2008
75. Boehringer Ingelheim. WO08022979; 2008
76. Boehringer Ingelheim. WO09103478; 2009
77. Bristol Myers Squibb. WO07050723; 2007
78. Bristol Myers Squibb. WO07050726; 2007
79. Bristol Myers Squibb. WO07092416; 2007
80. Bristol Myers Squibb. WO08134480; 2008
81. Bristol Myers Squibb. WO09009501; 2009
82. Bristol Myers Squibb. WO09146365; 2009
83. Bristol Myers Squibb. WO10042682; 2010
84. Bristol Myers Squibb. WO10042674; 2010
85. Bristol Myers Squibb. WO10047956; 2010
86. Bristol Myers Squibb. WO10104818; 2010
87. Bristol Myers Squibb. WO10104830; 2010
88. Cerep. WO07012661; 2007
89. Cerep. WO07012670; 2007.
90. Eli Lilly. WO06066174; 2006
91. Eli Lilly. WO08076562; 2008
92. Eli Lilly. WO06066173; 2006
93. Eli Lilly. WO07146759; 2007
94. Eli Lilly. WO07146758; 2007
95. Hertzog DL, Witty DR. Biphenyl amides and isosteres as MCH R1 antagonists. Curr Top Med Chem 2007;7:1455-70 (Pubitemid 47628329)
96. GlaxoSmithKline. WO09076387; 2009.
97. Hoffmann La Roche. WO08065021; 2008
98. Janssen. WO07071646; 2007
99. Janssen. WO08068265; 2008.
100. Korea Research Institute. WO08140239; 2008
101. Lundbeck. WO06041635; 2006.
102. Lundbeck. WO06041636; 2006.
103. Lundbeck. US20060079523; 2006.
104. Lundbeck. US20060079524; 2006.
105. Lundbeck. WO07114902; 2007.
106. Lundbeck. WO07114916; 2007.
107. Lundbeck. WO09120655; 2009.
108. Lundbeck. WO09137270; 2009.
109. Neurogen. WO06015279; 2006.
110. Neurogen. WO06044174; 2006.
111. Neurogen. WO08016811; 2008.
112. Pfizer. WO08041090; 2008.
113. Procter & Gamble. WO08002575; 2008.
114. Procter & Gamble. WO08001160; 2008.
115. Sanofi-Aventis. WO07042660; 2007.
116. Sanofi-Aventis. WO07042668; 2007.
117. Sanofi-Aventis. WO07042669; 2007.
118. Sanofi-Aventis. WO07093366; 2007.
119. Sanofi-Aventis. WO09021740; 2009.
120. Sanofi-Aventis. WO10092153 2010.
121. Sanofi-Aventis. WO10092154 2010.
122. Schering-Plough. WO06019957; 2006.
123. Taisho. WO06035967; 2006.
124. Taisho. WO05095357; 2005.
125. Taisho. WO04087680; 2004.
126. Taisho. EP01464335; 2003.
127. Taisho. WO08044632; 2008.
128. Taisho. WO10038901 2010.
129. Takeda. WO09123194; 2009 Equivalent of EP2261213.
130. Takeda. WO10087454 2010.
131. Redfern W, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58(1):32-45 (Pubitemid 36351620)